TELA vs. NYXH, ZIMV, SMTI, SNWV, STIM, CATX, TCMD, NVRO, SGHT, and DRTS
Should you be buying TELA Bio stock or one of its competitors? The main competitors of TELA Bio include Nyxoah (NYXH), ZimVie (ZIMV), Sanara MedTech (SMTI), SANUWAVE Health (SNWV), Neuronetics (STIM), Perspective Therapeutics (CATX), Tactile Systems Technology (TCMD), Nevro (NVRO), Sight Sciences (SGHT), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
TELA Bio vs.
Nyxoah (NASDAQ:NYXH) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
TELA Bio has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
TELA Bio has a net margin of -60.49% compared to Nyxoah's net margin of -1,043.93%. Nyxoah's return on equity of -51.68% beat TELA Bio's return on equity.
TELA Bio received 18 more outperform votes than Nyxoah when rated by MarketBeat users. However, 73.68% of users gave Nyxoah an outperform vote while only 73.17% of users gave TELA Bio an outperform vote.
94.3% of TELA Bio shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 4.7% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, TELA Bio had 3 more articles in the media than Nyxoah. MarketBeat recorded 8 mentions for TELA Bio and 5 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.54 beat TELA Bio's score of 0.89 indicating that Nyxoah is being referred to more favorably in the media.
Nyxoah presently has a consensus price target of $14.50, indicating a potential upside of 85.90%. TELA Bio has a consensus price target of $7.25, indicating a potential upside of 277.60%. Given TELA Bio's higher possible upside, analysts plainly believe TELA Bio is more favorable than Nyxoah.
Nyxoah has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Summary
Nyxoah and TELA Bio tied by winning 9 of the 18 factors compared between the two stocks.
Get TELA Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TELA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TELA Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TELA) was last updated on 6/11/2025 by MarketBeat.com Staff
